The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
27
07
2020
accepted:
23
09
2020
entrez:
3
2
2021
pubmed:
4
2
2021
medline:
4
2
2021
Statut:
epublish
Résumé
Currently there is major lack of agreement on the diagnostic and therapeutic management of patients with idiopathic pulmonary fibrosis (IPF) and lung cancer. Our aim was to identify variations in diagnostic and management strategies across different institutions and provide rationale for a consensus statement on this issue. This was a joint-survey by European Respiratory Society (ERS) Assemblies 8, 11 and 12. The survey consisted of 25 questions. Four hundred and ninety-four (n=494) physicians from 68 different countries and five continents responded to the survey. Ninety-four per cent of participants were pulmonologists, 1.8% thoracic surgeons and 1.9% oncologists; 97.7% were involved in multidisciplinary team approaches on diagnosis and management. Regular low-dose high-resolution computed tomography (HRCT) scan was used by 49.5% of the respondents to screen for lung cancer in IPF. Positron emission tomography (PET) scan and endobronchial ultrasound (EBUS) is performed by 60% and 88% to diagnose nodular lesions with mediastinal lymphadenopathy in patients with advanced and mild IPF, respectively. Eighty-three per cent of respondents continue anti-fibrotics following lung cancer diagnosis; safety precautions during surgical interventions including low tidal volume are applied by 67%. Stereotactic radiotherapy is used to treat patients with advanced IPF (diffusing capacity of the lung for carbon monoxide ( The diagnosis and management of IPF-lung cancer (LC) is heterogeneous with most respondents calling for a consensus statement.
Sections du résumé
BACKGROUND
BACKGROUND
Currently there is major lack of agreement on the diagnostic and therapeutic management of patients with idiopathic pulmonary fibrosis (IPF) and lung cancer. Our aim was to identify variations in diagnostic and management strategies across different institutions and provide rationale for a consensus statement on this issue.
METHODS
METHODS
This was a joint-survey by European Respiratory Society (ERS) Assemblies 8, 11 and 12. The survey consisted of 25 questions.
RESULTS
RESULTS
Four hundred and ninety-four (n=494) physicians from 68 different countries and five continents responded to the survey. Ninety-four per cent of participants were pulmonologists, 1.8% thoracic surgeons and 1.9% oncologists; 97.7% were involved in multidisciplinary team approaches on diagnosis and management. Regular low-dose high-resolution computed tomography (HRCT) scan was used by 49.5% of the respondents to screen for lung cancer in IPF. Positron emission tomography (PET) scan and endobronchial ultrasound (EBUS) is performed by 60% and 88% to diagnose nodular lesions with mediastinal lymphadenopathy in patients with advanced and mild IPF, respectively. Eighty-three per cent of respondents continue anti-fibrotics following lung cancer diagnosis; safety precautions during surgical interventions including low tidal volume are applied by 67%. Stereotactic radiotherapy is used to treat patients with advanced IPF (diffusing capacity of the lung for carbon monoxide (
CONCLUSION
CONCLUSIONS
The diagnosis and management of IPF-lung cancer (LC) is heterogeneous with most respondents calling for a consensus statement.
Identifiants
pubmed: 33532484
doi: 10.1183/23120541.00529-2020
pii: 00529-2020
pmc: PMC7837280
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©ERS 2021.
Déclaration de conflit d'intérêts
Conflict of interest: A. Tzouvelekis has received travel grants and consultation fees from Boehringer Ingelheim and Hoffmann La Roche outside the submitted work. Conflict of interest: K. Antoniou has received travel grants and consultation fees from Boehringer Ingelheim and Hoffmann La Roche. Conflict of interest: M. Kreuter has nothing to disclose. Conflict of interest: M. Evison has nothing to disclose. Conflict of interest: T.G. Blum has nothing to disclose. Conflict of interest: V. Poletti has nothing to disclose. Conflict of interest: B. Grigoriu has nothing to disclose. Conflict of interest: C. Vancheri has received unrestricted grants, and speaker and advisory board fees from Boehringer Ingelheim and F. Hoffmann-La Roche Ltd. Conflict of interest: P. Spagnolo reports grants, personal fees and nonfinancial support from Roche, PPM Services and Boehringer-Ingelheim, and reports personal fees from Red X Pharma, Galapagos and Chiesi, outside of the submitted work. Conflict of interest: T. Karampitsakos has nothing to disclose. Conflict of interest: F. Bonella has received travel grants and consultation fees from Boehringer Ingelheim, Hoffmann La Roche, Galapalagos, Savara and BMS. Conflict of interest: A. Wells has received travel grants and consultation fees from Boehringer Ingelheim and Hoffmann La Roche. Conflict of interest: G. Raghu has nothing to disclose. Conflict of interest: M. Molina-Molina reports grants and payment for scientific advice for Roche, Boehringer Ingelheim, Esteve-Teijin, Chiesi, Pfizer, GSK and Galapagos. Conflict of interest: D. Culver has nothing to disclose. Conflict of interest: E. Bendstrup has nothing to disclose. Conflict of interest: N. Mogulkoc has nothing to disclose. Conflict of interest: S. Elia has nothing to disclose. Conflict of interest: J. Cadranel reports grants from BI, and personal fees for consultancy and experts boards from Roche and BI, outside the submitted work. Conflict of interest: D. Bouros reports grants, personal fees, nonfinancial support and other support from BI Hellas, and other support from Roche, outside the submitted work.
Références
Palliat Med. 2013 Oct;27(9):869-76
pubmed: 23885010
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 05;31(4):266-74
pubmed: 25591137
Eur Respir J. 2005 Oct;26(4):586-93
pubmed: 16204587
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):622-631
pubmed: 28581404
J Thorac Oncol. 2011 Apr;6(4):801-7
pubmed: 21336181
Lancet Respir Med. 2014 Dec;2(12):979-87
pubmed: 25465642
J Thorac Dis. 2018 Jun;10(6):3829-3844
pubmed: 30069384
J Cancer Res Clin Oncol. 2016 Aug;142(8):1855-65
pubmed: 27350261
Respirology. 2009 Jul;14(5):723-8
pubmed: 19659650
J Thorac Cardiovasc Surg. 2014 May;147(5):1604-1611.e3
pubmed: 24267779
N Engl J Med. 2000 May 4;342(18):1301-8
pubmed: 10793162
Ann Intern Med. 2014 Mar 4;160(5):330-8
pubmed: 24378917
Pulm Pharmacol Ther. 2017 Aug;45:1-10
pubmed: 28377145
Eur Respir J. 2016 Jan;47(1):243-53
pubmed: 26647432
Respiration. 2014;87(4):287-93
pubmed: 24577160
Respir Med. 2007 Dec;101(12):2534-40
pubmed: 17870458
Lancet Respir Med. 2017 Dec;5(12):968-980
pubmed: 29033267
Radiat Oncol. 2016 Apr 18;11:56
pubmed: 27090216
Lancet. 2006 Feb 11;367(9509):474
pubmed: 16473123
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Respirol Case Rep. 2017 Aug 11;5(6):e00257
pubmed: 28811904
Cancer Chemother Pharmacol. 2015 Jul;76(1):69-74
pubmed: 25976217
Lancet Respir Med. 2018 Feb;6(2):86-88
pubmed: 29241977
Gen Thorac Cardiovasc Surg. 2010 Jul;58(7):356-83
pubmed: 20628854
Ann Thorac Surg. 2016 Dec;102(6):1905-1910
pubmed: 27546601
Sci Transl Med. 2018 Sep 26;10(460):
pubmed: 30257954
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Thorax. 2015 Sep;70(9):830-9
pubmed: 26103995
Lancet Oncol. 2014 Feb;15(2):143-55
pubmed: 24411639
Lung Cancer. 2017 Feb;104:111-118
pubmed: 28212992
Eur Respir J. 2010 Mar;35(3):496-504
pubmed: 20190329
Pulm Pharmacol Ther. 2020 Feb;60:101880
pubmed: 31874284
Lancet Respir Med. 2018 Feb;6(2):82-84
pubmed: 29154105
Respiration. 2013;85(4):326-31
pubmed: 23171837
Chest. 2015 Jan;147(1):157-164
pubmed: 25166895
Eur Respir J. 2001 Jun;17(6):1216-9
pubmed: 11491167
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1115-9
pubmed: 10988139
PLoS One. 2016 Mar 29;11(3):e0151425
pubmed: 27023440